Active Substance: Glimepiride.
Overview
Welcome to Dwaey, specifically on G PRIDE 1 page.
This medicine contains an important and useful components, as it consists of
Glimepirideis available in the market in concentration
Glimepiride
Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation. Lactation: Excretion in milk unknown; avoid
Type 2 DM
Diabetic ketoacidosis with or without coma.
>10% Hypoglycemia (4-20%) 1-10% Dizziness (1.7%),Asthenia (1.6%),Headache (1.5%),Nausea (1.1%) <1% Allergic skin reactions,Erythema,Morbilliform or maculopapular eruptions,Pruritus,Urticaria,Diarrhea,Gastrointestinal pain,Vomiting,Agranulocytosis,Anemia,Aplastic anemia,Leukopenia,Pancytopenia,Thrombocytopenia, hemolytic,Cholestasis,Elevation of liver enzyme levels,Hepatic porphyria reactions,Jaundice (rare),Disulfiram-like reactions,Hyponatremia
3
Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
Information not available